Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

Cardiovasc Diabetol

7 Aprile Apr 2023 one year ago
  • Cosentino N, Bonomi A, Poggio P, Agostoni P, Genovese S, Marenzi G.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) demonstrated cardiovascular and renal protection. Whether their benefits occur also during hospitalization for acute myocardial infarction (AMI) in patients with diabetes mellitus (DM) is not known. We evaluated in-hospital outcomes of patients hospitalized with AMI according to their chronic use of GLP-1 RA and/or SGLT-2i.

Reference: Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction.
Trombara F, Cosentino N, Bonomi A, Ludergnani M, Poggio P, Gionti L, Baviera M, Colacioppo P, Roncaglioni MC, Leoni O, Bortolan F, Agostoni P, Genovese S, Marenzi G.
Cardiovasc Diabetol. 2023 Feb 6;22(1):26.

Go to PubMed